Meet Our Team
|
Jeremy Elser, PHD
Founding CEO Dr. Elser is the founding CEO of Ship of Theseus. Working at Palantir, he has led the digital transformation team of a global life science and pharmaceutical manufacturer over the course of 5 years. He authored How to Talk to Data Scientists: A Guide for Executives (BEP 2021) and cofounded Buyside, the real estate data analytics platform powering over 100 of the top U.S. real estate brokers. His degrees include a doctorate in Bioengineering from the University of Pennsylvania, where his research focused on stem cell therapy for myocardial infarctions, and a B.S. in Biomedical Engineering from Johns Hopkins University. |
|
Kelsey Moody, PHD MBA
Advisor, Pipeline Development Dr. Moody serves as a co-Founder and CEO of Ichor, a therapeutics and contract research organization specializing in protein synthesis and pharmacology. Dr. Moody has led the development of Ichor's portfolio of companies spanning enzyme therapy (Lysoclear), senolytics (FoxBio), small molecule drug delivery (Antoxerene), and antibody mimetics (Auctus). Dr. Moody brings a wealth of preclinical planning and execution experience to Ship of Theseus as well as the facilities and technical capacity of Ichor. |
|
Aaron Wolfe, PHD
Scientific Advisor, Protein and Plasmid Synthesis Dr. Wolfe serves as CSO of Ichor and specializes in synthesis and purification of complex proteins. Prior to joining Ichor, he co-founded Finger Lakes Bio, a boutique protein engineering company. He previously served as biotechnology consultant to RLH, a private investment company. Dr. Wolfe holds a PhD in structural biology, biochemistry, and biophysics from Syracuse University and a certificate in entrepreneurship from the Wharton School. He brings expertise and troubleshooting capability in the design, manufacturing, and CMC to Ship of Theseus. |
|
Pengbo Zhou, PHD
Scientific Advisor, LEXE Modification Inventor Dr. Zhou has been a professor at Weill Cornell Medical College for over 20 years currently serves as a Professor of Pathology and Laboratory Medicine. He led the studies that discovered that HOX family member degradation is dependent on CUL4A. By elucidating the mechanism of HOXB4 degradation, his laboratory was then able to generate and invent a sequence variant that improved intracellular half-life of HOX proteins via escape from the ubiquination process. |
|
Nancy Boudreau, PHD
Scientific Advisor, HOXA3 diabetic wound expert Throughout Dr. Boudreau's 25-year research career, her lab focused on the Homeobox family and angiogenesis in the context of wound repair, skin remodeling, and cancer. Specifically, Dr. Boudreau and collaborators pioneered the research that established HOXA3 as a mediator of wound healing and were the first to demonstrate the localized transfer of HOXA3 with methylcellulose to a wound could be used to improve healing in animal subjects with impaired healing capabilities, like diabetic patients. Dr. Boudreau was previously a Professor in the Department of Surgery at University of California San Francisco, the Branch Chief of the Tumor Metastasis Branch at the National Cancer Institute, and is now a Research Scientist at Weill Cornell Medical College. |
|
Mona Povlick, CPA
Senior Lead Accountant Ms. Povlick brings over 30 years of accounting expertise to Ship of Theseus. She is a Senior Lead in the Accounting and Compliance Department at Eva Garland Consulting, LLC., which is a nationally recognized leader in providing accounting and compliance services to companies who have received Federal Grants and Contracts. Ms. Povlick received her Accounting Degree from North Carolina State University and is a North Carolina Certified Public Accountant. |